MedWatch

Lundbeck loses top-line terrain but surpasses expectations

Sales of the drug Northera, which is no longer protected by patents, plummeted in Lundbeck's first quarter, while most other key products surpassed analysts' forecasts. This means the firm brought in more revenue than the market expected.

Photo: Jens Dresling

Lundbeck maintains its guidance for 2021 since the company's first quarter ended significantly better than what the market had expected.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs